- Home
- SACH vs OTLK Comparison
SACH vs OTLK Comparison
Compare SACH & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SACH
- OTLK
- Stock Information
- Founded
- SACH 2010
- OTLK 2010
- Country
- SACH United States
- OTLK United States
- Employees
- SACH N/A
- OTLK N/A
- Industry
- SACH Real Estate Investment Trusts
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SACH Real Estate
- OTLK Health Care
- Exchange
- SACH Nasdaq
- OTLK Nasdaq
- Market Cap
- SACH 47.8M
- OTLK 48.3M
- IPO Year
- SACH 2017
- OTLK 2016
- Fundamental
- Price
- SACH $0.98
- OTLK $1.53
- Analyst Decision
- SACH Hold
- OTLK Strong Buy
- Analyst Count
- SACH 3
- OTLK 5
- Target Price
- SACH $2.25
- OTLK $10.20
- AVG Volume (30 Days)
- SACH 201.6K
- OTLK 274.9K
- Earning Date
- SACH 05-01-2025
- OTLK 05-19-2025
- Dividend Yield
- SACH 18.46%
- OTLK N/A
- EPS Growth
- SACH N/A
- OTLK N/A
- EPS
- SACH N/A
- OTLK N/A
- Revenue
- SACH N/A
- OTLK N/A
- Revenue This Year
- SACH N/A
- OTLK N/A
- Revenue Next Year
- SACH N/A
- OTLK $288.46
- P/E Ratio
- SACH N/A
- OTLK N/A
- Revenue Growth
- SACH N/A
- OTLK N/A
- 52 Week Low
- SACH $0.96
- OTLK $0.87
- 52 Week High
- SACH $3.24
- OTLK $9.25
- Technical
- Relative Strength Index (RSI)
- SACH 40.88
- OTLK 55.94
- Support Level
- SACH $0.96
- OTLK $1.35
- Resistance Level
- SACH $1.05
- OTLK $1.62
- Average True Range (ATR)
- SACH 0.04
- OTLK 0.10
- MACD
- SACH -0.00
- OTLK -0.00
- Stochastic Oscillator
- SACH 14.50
- OTLK 54.55
About SACH Sachem Capital Corp.
Sachem Capital Corp is a real estate investment trust. The company specializes in originating, underwriting, funding, servicing, and managing a portfolio of short-term loans secured by first mortgage liens on real property located in Connecticut. Its primary objective is to grow the loan portfolio while protecting and preserving capital in a manner that provides for attractive risk-adjusted returns to shareholders over the long term through dividends. The company earns majority of its revenue through Interest income from loans.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.